(Inside Science TV) -- One in 8 women will be diagnosed with breast cancer in their lifetime. You have probably either had, will have, or know somebody who has had breast cancer. Why one person gets the disease and another doesn’t is not completely known. What doctors do know is that breast cancer can be caused by damaged DNA inside a cell. The good news is earlier detection, increased awareness, better treatments and technology means it’s more likely than ever before patients will survive it. "Many women have a phase called non-invasive cancer," said Seema Khan, a surgical oncologist at Northwestern University in Evanston, Illinois. Non-invasive cancer is confined to a woman's milk ducts or breast lobes and has not spread beyond the breast tissue. Anti-hormone drugs are a common treatment for this type of breast cancer. You’ve finished treatment for breast cancer and your oncologist has said you are cancer-free “as far as we know.” But one tussle with the Big C is enough; you don’t want a recurrence. Or maybe you have a high risk of getting breast cancer. Perhaps you have a strong family history, genetic predisposition and/or have had some concerning biopsies. You don’t want to have to face cancer; you’d rather try to prevent it in the first place. Either way, you’re a good candidate — if you’re premenopausal — for tamoxifen. A powerful chemotherapy treatment that’s been used for more than 30 years, tamoxifen decreases the chances of breast cancer occurrence or recurrence by about 50%, according to Worta Mc Caskill-Stevens, MD, MS, medical oncologist and Chief of the Community Oncology and Prevention Trials Research Group at the National Cancer Institute. That benefit doesn’t disappear the minute you pop your last pill, either. Buy blue ventolin inhaler Viagra reviews forums Order genuine cialis A new study shows that a gel form of commonly used cancer drug tamoxifen is just as effective as the oral form and produces fewer side effects. A novel tamoxifen gel that is applied directly to the breast produces antiproliferative effects in breast tissue similar to those produced by oral tamoxifen, but with fewer adverse effects, a. PHILADELPHIA — A breakdown product of tamoxifen, 4-OHT, applied as a gel formulation on the breasts of women with ductal carcinoma in situ DCIS, was as. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. This randomized phase IIB trial studies how well tamoxifen or afimoxifene works in treating patients with estrogen receptor positive breast cancer. Listing a study does not mean it has been evaluated by the U. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate or afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells. To demonstrate that 2 mg once daily per breast of 4-hydroxytamoxifen (4-OHT) topical gel results in a reduction in the Ki-67 labeling index of ductal breast carcinoma in situ (DCIS) lesions that is not inferior to that seen with 20 mg daily oral tamoxifen citrate (TAM) for 8±2 weeks weeks weeks, when comparing the base-line diagnostic core biopsy to the therapeutic surgical excision sample. To compare post-therapy changes in the oncotype DCIS-score between arms (this is a validated reverse transcriptase-polymerase chain reaction [RT-PCR] assay for Ki67, STK15, survivin, cyclin B1, MYBL2, PR, GSTM1). To compare between-group post-therapy changes in immunohistochemistry (IHC) markers: CD-68 macrophage marker as a surrogate for response to therapy, p16 and COX-2. To compare post-therapy changes in breast density, quantitative estimate, between arms. To compare post-therapy breast tissue and plasma levels of TAM and its metabolites (N-desmethyl tamoxifen [NDT], [E] and [Z] isomers of 4-hydroxytamoxifen [4-OHT], N-desmethyl-4-hydroxytamoxifen [endoxifen]). To compare post-therapy breast tissue and plasma levels of estradiol and progesterone between arms (optional). To compare the post-therapy fraction of participants demonstrating "no residual DCIS". To compare post-therapy changes in plasma proteins involved in coagulation: factors VIII and IX, von Willebrand factor, total protein S between arms. To compare post-therapy changes in plasma markers of systemic estrogenic effect (IGF-1, SHBG). To compare post-therapy changes in symptoms as captured in the breast cancer prevention trial (BCPT) Eight Symptom Scale (BESS) questionnaire and skin reactions to 4-OHT gel. ARM I: Patients apply afimoxifene gel to both breasts and receive placebo orally (PO) daily for 8±2 weeks in the absence of disease progression or unexpected toxicity. ARM II: Patients apply placebo gel to both breasts and receive tamoxifen citrate orally PO daily for 8±2 weeks in the absence of disease progression or unexpected toxicity. NIH Grant/Contract ) NCI-2016-01911 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) N01-CN-2012-000-06-04 ( Other Identifier: Northwestern University ) NWU2015-06-04 ( Other Identifier: DCP ) N01CN00035 ( U. After completion of study treatment, patients are followed up at 1-2 weeks and 1 month after surgery. Omen with the most common form of breast cancer may find that their treatment plans include tamoxifen. Tamoxifen is one of the most frequently-used chemotherapy drugs though it is somewhat controversial. When it comes to any kind of breast cancer chemotherapy, there’s a lot to think about. If you have a high-risk profile for breast cancer, or if you’ve been diagnosed with the disease, you may be asking, or SERM. Tamoxifen and raloxifene, a similar drug, are the only medications to be FDA-approved for prevention of breast cancer in women who are at higher risk because of familial risk factors. Only tamoxifen can be used for prevention in all women, and raloxifene can only be used in postmenopausal women. Tamoxifen has also been used as a primary treatment for some early stage forms of cancer and as a secondary, or , meaning they affect how hormones work. Tamoxifen gel availability Testing an Active Form of Tamoxifen 4. - ClinicalTrials.gov, Novel Tamoxifen Gel Could Reduce Adverse Effects - Medscape Will zoloft help you sleepBuy accutane with paypalWhere to buy cialis in michigan Testing an Active Form of Tamoxifen 4-hydroxytamoxifen Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ DCIS of the Breast The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Testing an Active Form of Tamoxifen 4-hydroxytamoxifen.. Tamoxifen Gel Effective When Applied to Breast, With Fewer Side.. Inhibition of breast cancer with transdermal.. Tamoxifen has been in use for over 30 years as a selective estrogen receptor modulator, or SERM, which is a drug that prevents breast cancer in high risk women. Oral low dose and topical tamoxifen for breast cancer. randomized to either oral tamoxifen 20 mg/day or a 4-OHT gel at a dose of 4 mg/breast/day. A randomized phase II presurgical trial of transdermal 4-Hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.